Embecta (EMBC) Competitors $14.25 -0.05 (-0.35%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$13.94 -0.31 (-2.18%) As of 10/22/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EMBC vs. LIVN, WRBY, INSP, EYE, LQDA, LMAT, AORT, PRCT, ENOV, and CDREShould you be buying Embecta stock or one of its competitors? The main competitors of Embecta include LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), National Vision (EYE), Liquidia Technologies (LQDA), LeMaitre Vascular (LMAT), Artivion (AORT), PROCEPT BioRobotics (PRCT), Enovis (ENOV), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. Embecta vs. Its Competitors LivaNova Warby Parker Inspire Medical Systems National Vision Liquidia Technologies LeMaitre Vascular Artivion PROCEPT BioRobotics Enovis Cadre Embecta (NASDAQ:EMBC) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment. Is EMBC or LIVN more profitable? Embecta has a net margin of 7.58% compared to LivaNova's net margin of -16.13%. LivaNova's return on equity of 14.57% beat Embecta's return on equity.Company Net Margins Return on Equity Return on Assets Embecta7.58% -23.40% 14.46% LivaNova -16.13%14.57%6.91% Do analysts rate EMBC or LIVN? Embecta presently has a consensus price target of $19.00, suggesting a potential upside of 33.33%. LivaNova has a consensus price target of $59.71, suggesting a potential upside of 8.87%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than LivaNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Embecta 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20LivaNova 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger earnings & valuation, EMBC or LIVN? Embecta has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmbecta$1.12B0.74$78.30M$1.439.97LivaNova$1.25B2.39$63.23M-$3.89-14.10 Do insiders and institutionals have more ownership in EMBC or LIVN? 93.8% of Embecta shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 0.4% of Embecta shares are held by company insiders. Comparatively, 0.3% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, EMBC or LIVN? Embecta has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Does the media refer more to EMBC or LIVN? In the previous week, LivaNova had 3 more articles in the media than Embecta. MarketBeat recorded 4 mentions for LivaNova and 1 mentions for Embecta. Embecta's average media sentiment score of 1.79 beat LivaNova's score of 1.73 indicating that Embecta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive LivaNova 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryEmbecta beats LivaNova on 9 of the 16 factors compared between the two stocks. Get Embecta News Delivered to You Automatically Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EMBC vs. The Competition Export to ExcelMetricEmbectaMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$836.34M$8.51B$6.16B$10.67BDividend Yield4.20%2.11%5.72%4.86%P/E Ratio9.9775.6429.0927.13Price / Sales0.7439.65582.26126.20Price / Cash4.2921.5437.1261.42Price / Book-1.117.0712.146.43Net Income$78.30M$250.93M$3.33B$276.63M7 Day Performance4.09%-0.74%-0.76%-0.77%1 Month Performance-2.20%-2.99%5.30%0.68%1 Year Performance1.64%12.92%67.61%32.03% Embecta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EMBCEmbecta4.7139 of 5 stars$14.25-0.3%$19.00+33.3%+0.6%$836.34M$1.12B9.972,100Positive NewsLIVNLivaNova2.8371 of 5 stars$51.78+2.2%$59.71+15.3%+2.9%$2.77B$1.25B-13.312,900Positive NewsWRBYWarby Parker2.308 of 5 stars$22.17-0.4%$24.75+11.7%+22.6%$2.34B$821.35M-316.613,780INSPInspire Medical Systems4.8199 of 5 stars$77.57+3.2%$150.50+94.0%-58.7%$2.22B$802.80M44.841,246Positive NewsEYENational Vision2.6688 of 5 stars$26.37+3.2%$24.73-6.2%+165.5%$2.02B$1.82B-146.5013,411LQDALiquidia Technologies3.6059 of 5 stars$23.77+2.5%$32.38+36.2%+99.5%$2.00B$14M-13.9850Analyst ForecastLMATLeMaitre Vascular3.3844 of 5 stars$85.31-0.9%$97.60+14.4%+3.2%$1.95B$219.86M41.41490AORTArtivion2.6875 of 5 stars$40.63+1.1%$43.97+8.2%+63.7%$1.90B$405.04M-96.741,600PRCTPROCEPT BioRobotics2.8296 of 5 stars$33.00+0.2%$70.00+112.1%-48.5%$1.83B$224.50M-21.29430Upcoming EarningsENOVEnovis3.6924 of 5 stars$29.76+0.2%$51.00+71.4%-18.2%$1.70B$2.19B-2.097,367CDRECadre3.1728 of 5 stars$39.03+1.7%$37.50-3.9%+9.2%$1.56B$572.61M41.522,284Dividend Announcement Related Companies and Tools Related Companies LIVN Alternatives WRBY Alternatives INSP Alternatives EYE Alternatives LQDA Alternatives LMAT Alternatives AORT Alternatives PRCT Alternatives ENOV Alternatives CDRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EMBC) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
